20.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$19.75
Aprire:
$19.91
Volume 24 ore:
1.54M
Relative Volume:
0.64
Capitalizzazione di mercato:
$15.26B
Reddito:
$956.00K
Utile/perdita netta:
$-196.68M
Rapporto P/E:
-86.21
EPS:
-0.24
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
+2.78%
1M Prestazione:
+9.82%
6M Prestazione:
-13.79%
1 anno Prestazione:
+513.95%
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SMMT
Summit Therapeutics Inc
|
20.69 | 15.26B | 956.00K | -196.68M | -113.02M | -0.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
511.74 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
661.00 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
290.70 | 37.63B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ARGX
Argen X Se Adr
|
607.95 | 37.08B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ONC
Beigene Ltd Adr
|
253.20 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
2025-03-12 | Iniziato | Evercore ISI | Outperform |
2025-02-28 | Iniziato | Goldman | Buy |
2025-01-08 | Iniziato | Truist | Buy |
2024-12-11 | Iniziato | Wells Fargo | Overweight |
2024-12-06 | Iniziato | Jefferies | Buy |
2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
2024-08-12 | Iniziato | H.C. Wainwright | Buy |
2024-05-07 | Iniziato | Citigroup | Buy |
2024-03-26 | Iniziato | Stifel | Buy |
2018-06-28 | Downgrade | Janney | Buy → Neutral |
2018-05-02 | Iniziato | Janney | Buy |
2018-04-12 | Reiterato | Needham | Buy |
2018-02-13 | Iniziato | BTIG Research | Buy |
2018-01-04 | Iniziato | SunTrust | Buy |
2017-12-01 | Ripresa | H.C. Wainwright | Buy |
2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
2016-10-05 | Reiterato | Needham | Buy |
2016-09-16 | Iniziato | H.C. Wainwright | Buy |
2015-03-30 | Iniziato | Needham | Buy |
2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga
Summit CEO Bob Duggan Sued Over 'Outlandish' Self-Dealing Loan - Bloomberg Law
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Overweight Recommendation - Nasdaq
Summit rises as Cantor becomes latest to launch with a bullish view - MSN
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - Nasdaq
Summit Therapeutics grants stock options to new employees By Investing.com - Investing.com Canada
Summit Therapeutics grants stock options to new employees - Investing.com India
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:20 pm EDT - Marketscreener.com
Summit Therapeutics Awards 147,500 Shares in Strategic Employee Stock Options - StockTitan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Summit stock rises after Cantor's bullish view (SMMT:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Summit Therapeutics at Overweight -March 21, 2025 at 07:27 am EDT - Marketscreener.com
This Unstoppable Biotech Stock Just Became an Even Better Buy - The Globe and Mail
Summit Therapeutics Names Robert LaCaze as Chief Commercial Officer -March 18, 2025 at 03:30 am EDT - Marketscreener.com
Summit Therapeutics : Completion of $50 million Fundraising and Directorate Change - Marketscreener.com
Billion-Dollar Oncology Expert Robert LaCaze to Drive Summit Therapeutics Cancer Drug Launch - StockTitan
Evercore ISI Group Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Outperform Recommendation - Nasdaq
Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SMMT - Benzinga
(SMMT) On The My Stocks Page - Stock Traders Daily
Summit Therapeutics issues stock options to new employees By Investing.com - Investing.com Australia
Summit Therapeutics issues stock options to new employees - Investing.com India
Summit Therapeutics Awards 122,650 Shares in Employee Stock Options at $18.50 - StockTitan
Summit Therapeutics Stock Climbs 4%, Share Price Hits $19.96 - TradingPedia
Why Summit Therapeutics Stock Was Winning This Week - MSN
SMMT Gains on Bullish Analyst Coverage - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISI - Defense World
Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? - Insider Monkey
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Nasdaq
Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com
Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks
Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq
Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey
Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey
New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat
Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):